When was Boomray founded?

Boomray was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Boomray located?

Boomray is headquartered in Changping District, China.

Is Boomray a funded company?

Boomray is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 05, 2022.

When was the latest funding round of Boomray?

Boomray's latest funding was a $***** Series A round on Sep 05, 2022, with participation from 4 investors.

Where does Boomray rank among its competitors?

Boomray ranks 973rd amongst 2539 active competitors, of which 868 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Boomray?

Boomray's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Boomray - 2026 Company Profile, Team, Funding & Competitors

Boomray is a series A company based in Changping District (China), founded in 2021. It operates as a Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer. Boomray has raised $43M in funding from Sequoia Capital China. The company has 2539 active competitors, including 868 funded and 627 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer. The company's pipeline includes multiple FIC/BIC nuclide conjugated drugs and neutron capture therapy drugs, involving multiple different indications including head and neck tumors, brain tumors, pancreatic cancer, inflammatory cancer identification, and other diagnostic applications.

Website: boomray.com
Email ID: *****@boomray.com
Phone Number: +86 **********

Key Metrics

Founded Year

2021

Location

Changping District, China

Stage

Series A

Total Funding

$43M in 1 round

Latest Funding Round

Series A, Sep 05, 2022, $*****

Investors

Sequoia Capital China & 3 more

Ranked

973^rd among 2539 active competitors

Similar Companies

RayzeBio & 105 more

View Boomray's full profile

Boomray has raised a total funding of $43M over 1 round. Its latest funding round was a Series A round on Sep 05, 2022 for $*****. 4 investors participated in its latest round. Boomray has 4 institutional investors.

Here is the list of recent funding rounds of Boomray:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2022	2072578	Series A	6270730	9130014	2278814	1004957

Access funding benchmarks and valuations. Sign up today!

View details of Boomray's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Boomray include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Boomray, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
973rd	Boomray 2021, Changping District (China), Series A	Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer	$43M	RiverHead Capital, CTS Capital & 2 others	37/100